Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

2.

Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension.

Hashimoto J, Ito S.

Hypertension. 2011 Nov;58(5):839-46. doi: 10.1161/HYPERTENSIONAHA.111.177469. Epub 2011 Oct 3.

3.

The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.

Currie CJ, Johnson JA.

Diabetes Obes Metab. 2012 Jan;14(1):1-4. doi: 10.1111/j.1463-1326.2011.01469.x. Epub 2011 Nov 21. Review.

PMID:
21736688
4.

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

Rensing KL, Reuwer AQ, Arsenault BJ, von der Thüsen JH, Hoekstra JB, Kastelein JJ, Twickler TB.

Diabetes Obes Metab. 2011 Dec;13(12):1073-87. doi: 10.1111/j.1463-1326.2011.01468.x. Review.

PMID:
21736687
5.

Insulin: potential negative consequences of early routine use in patients with type 2 diabetes.

Lebovitz HE.

Diabetes Care. 2011 May;34 Suppl 2:S225-30. doi: 10.2337/dc11-s225. No abstract available.

6.

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.

Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L; DIGAMI 2 Investigators.

Diabetologia. 2011 Jun;54(6):1308-17. doi: 10.1007/s00125-011-2084-x. Epub 2011 Feb 26.

PMID:
21359582
7.

Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries.

Liebl A, Jones S, Benroubi M, Castell C, Goday A, Aline Charles M, Smith HT, Nicolay C, Simpson A.

Curr Med Res Opin. 2011 May;27(5):887-95. doi: 10.1185/03007995.2011.555755. Epub 2011 Feb 22.

PMID:
21341946
8.

Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence?

Nandish S, Bailon O, Wyatt J, Smith J, Stevens A, Lujan M, Chilton R.

Curr Atheroscler Rep. 2011 Apr;13(2):123-8. doi: 10.1007/s11883-011-0165-4. Review.

PMID:
21287301
9.

Standards of medical care in diabetes--2011.

American Diabetes Association.

Diabetes Care. 2011 Jan;34 Suppl 1:S11-61. doi: 10.2337/dc11-S011. No abstract available.

10.

A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study.

Colayco DC, Niu F, McCombs JS, Cheetham TC.

Diabetes Care. 2011 Jan;34(1):77-83. doi: 10.2337/dc10-1318. Epub 2010 Oct 11.

11.

Intensified glucose lowering in type 2 diabetes: time for a reappraisal.

Yudkin JS, Richter B, Gale EA.

Diabetologia. 2010 Oct;53(10):2079-85. doi: 10.1007/s00125-010-1864-z. Epub 2010 Aug 5. No abstract available.

PMID:
20686748
12.

Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.

Currie CJ, Peters JR, Evans M.

Diabet Med. 2010 Jul;27(7):744-52. doi: 10.1111/j.1464-5491.2009.02849.x.

PMID:
20636954
13.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J.

Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L].

14.

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

Bowker SL, Yasui Y, Veugelers P, Johnson JA.

Diabetologia. 2010 Aug;53(8):1631-7. doi: 10.1007/s00125-010-1750-8. Epub 2010 Apr 21.

PMID:
20407744
15.

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence.

Nordin C.

Diabetologia. 2010 Aug;53(8):1552-61. doi: 10.1007/s00125-010-1752-6. Epub 2010 Apr 21. Review.

PMID:
20407743
16.

Validity of diagnostic coding within the General Practice Research Database: a systematic review.

Khan NF, Harrison SE, Rose PW.

Br J Gen Pract. 2010 Mar;60(572):e128-36. doi: 10.3399/bjgp10X483562. Review.

17.

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD.

Lancet. 2010 Feb 6;375(9713):481-9. doi: 10.1016/S0140-6736(09)61969-3. Epub 2010 Jan 26.

PMID:
20110121
18.

[Relationship between pulse pressure, visual impairement and severity of diabetic retinopathy in sub-Saharan Africa].

Nkondi Mbadi AN, Longo-Mbenza B, Mvitu Muaka M, Mbungu FS, Lemogoum D.

Mali Med. 2009;24(3):17-21. French.

PMID:
20093220
19.

Insulin use and increased risk of mortality in type 2 diabetes: a cohort study.

Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA.

Diabetes Obes Metab. 2010 Jan;12(1):47-53. doi: 10.1111/j.1463-1326.2009.01125.x. Epub 2009 Sep 24.

PMID:
19788429
20.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Currie CJ, Poole CD, Gale EA.

Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.

PMID:
19572116

Supplemental Content

Support Center